Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Storek, Jan  [Clear All Filters]
2023
Khan L, Derksen T, Redmond D, Storek J, Durand C, Gniadecki R, Korman B, Tervaert JWillem Coh, D'Aubeterre A, Osman MS, et al. The cancer-associated glycan polysialic acid is dysregulated in systemic sclerosis and is associated with fibrosis. J Autoimmun. 2023;140:103110.
Woo MMK, Levin D, Li DY, David J, Buresi M, Gupta M, Nasser Y, Andrews CN, Durand C, Osman MS, et al. Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation. Clin Rheumatol. 2023.
2022
Beland B, Hahn C, Jamani K, Chhibber S, White C, Atkins H, Storek J. Autologous Hematopoietic Stem Cell Transplant for the Treatment of Refractory Myasthenia Gravis with Anti-Muscle Specific Kinase Antibodies. Muscle Nerve. 2022.
Shah A, Storek J, Woolson R, Pinckney A, Keyes-Elstein L, Wallace PK, Sempowski GD, McSweeney P, Mayes MD, Crofford L, et al. Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapy. Rheumatology (Oxford). 2022.
2021
Burton JM, Duggan P, Costello F, Metz L, Storek J. A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. Mult Scler Relat Disord. 2021;53:102990.
Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, Chaudhry A, Shafey M, Jimenez-Zepeda V, Duggan P, et al. Risk factors for the incidence of PTLD and the mortality due to PTLD after hematopoietic cell transplantation. Transplant Cell Ther. 2021.
2020
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
2019
Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, et al. AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR TREATMENT-REFRACTORY RELAPSING MULTIPLE SCLEROSIS: POSITION STATEMENT FROM THE AMERICAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION. Biol Blood Marrow Transplant. 2019.
Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, et al. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.
2016
Faridi RMujeeb, Kemp TJ, Dharmani-Khan P, Lewis V, Tripathi G, Rajalingam R, Daly A, Berka N, Storek J, Khan FMasood. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. PLoS One. 2016;11(6):e0158242.